Aviceda raises $207.5 million in Series C funding to advance geographic atrophy program

Aviceda Therapeutics secured $207.5 million in Series C financing to advance the AVD-104 program in geographic atrophy, according to a press release.

Omega Funds and TCGX led the financing round. Contributors included Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, funds managed by abrdn Inc. and Digitalis Ventures. The funding will support the ongoing phase 2b/3 trial investigating AVD-104, as well as the planned pivotal phase 3 clinical trial.

As Healio previously reported, AVD-104 demonstrated safety, slower geographic atrophy (GA) lesion growth and clinically meaningful visual acuity improvements in part one of the phase 2/3 SIGLEC trial.

“This raise reflects the strong conviction from investors in Aviceda’s lead program AVD-104 for geographic atrophy — a market poised for disruption and an improved standard of care, given current treatments offer limited benefits in visual improvements, lesion control and safety,” David Guyer, MD, board chair of Aviceda, said in the release. “With this upsized financing, the company is well-capitalized to advance a pivotal program for AVD-104 in GA.”

Published by:

Read more about

This post was originally published on this site